These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 23151979)
1. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979 [TBL] [Abstract][Full Text] [Related]
2. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial). Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421 [TBL] [Abstract][Full Text] [Related]
3. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Steinherz PG; Shukla N; Kobos R; Steinherz L Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Martínez-Cuadrón D; Montesinos P; Oriol A; Salamero O; Vidriales B; Bergua J; Herrera P; Vives S; Sanz J; Carpio C; Rodríguez-Veiga R; Moscardó F; Sanz MA Ann Hematol; 2014 Jan; 93(1):43-6. PubMed ID: 24081577 [TBL] [Abstract][Full Text] [Related]
5. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514 [TBL] [Abstract][Full Text] [Related]
6. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688 [TBL] [Abstract][Full Text] [Related]
7. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494 [TBL] [Abstract][Full Text] [Related]
8. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926 [TBL] [Abstract][Full Text] [Related]
9. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153 [TBL] [Abstract][Full Text] [Related]
10. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931 [TBL] [Abstract][Full Text] [Related]
14. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
15. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia. Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139 [TBL] [Abstract][Full Text] [Related]
16. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474 [TBL] [Abstract][Full Text] [Related]
17. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905 [TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA; J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813 [TBL] [Abstract][Full Text] [Related]
19. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360 [TBL] [Abstract][Full Text] [Related]
20. Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Tse E; Leung AY; Sim J; Lee HK; Liu HS; Yip SF; Kwong YL Ann Hematol; 2011 Nov; 90(11):1277-81. PubMed ID: 21455604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]